产品可持续性

We follow processes throughout the life cycle of our products with the aim of understanding and addressing their environmental impact; from discovery through development and production, to launch of a new product and to end of product life.

澳门第一赌城在线娱乐的方法

People and the planet will benefit from those medicines which have the smallest possible environmental impact yet maintain the highest medical efficacy and safety standards. As technologies and healthcare systems evolve, 减少能源的解决方案也应该如此, 水, 材料使用, waste and pollution generated from designing, manufacturing and delivering medicines to patients. We know that the greenhouse gas emissions from our product value chains make the most significant contribution to our company Scope 3 emissions, and we are addressing these across our business using a data-driven approach.

We have implemented an internal Product 可持续性 Index (PSI) to understand the environmental impacts of our products and inform improvement plans. We also lead our industry in the management of 环境中的药物 and promote responsible product stewardship. 更多的 details of our approach can be found in our position statement on 环境中的药物.

Sustainable decision-making and environmental improvements are embedded across the product life cycle:

We have integrated business processes to ensure safety, health and environmental aspects are considered throughout drug development, with guidance on environmental assessment of active pharmaceutical ingredient (API) manufacturing, 配方, 包装和设备
We have targets for API manufacturing emissions from both AstraZeneca and our external supply sites
澳门第一赌城在线娱乐的行为, fund and support research on the environmental impact of our products and apply the principles of green chemistry in our business
Our life cycle assessment (LCA) programme determines the type and magnitude of environmental impacts across our product value chains and is in line with ISO standards 14040 and 14044
We invest in new science and disruptive technologies, allowing design of shorter chemical sequences to our APIs, and improve processes for our new modality medicines, significantly reducing environmental impact
We are working on redesigning our packaging to make it more sustainable
We are a leading partner in collaborations to drive common standards for illustrating environmental footprints of our medicines
Ecopharmacovigilance (EPV) is our approach to understanding pharmaceuticals in the environment. Our EPV process reviews emerging science and literature, looking for new information that might change the way we assess the environmental risks associated with our APIs. 澳门第一赌城在线娱乐的行业领先 Ecopharmacovigilance dashboard, users can visualise the relative risks of our APIs that are found in the environment.. 中的数据是透明的环境风险评估澳门第一赌城在线娱乐网站上的文件.
As part of our commitment to drive thought leadership and innovation to manage PIE, 澳门第一赌城在线娱乐是行业的领先者创新健康倡议(IHI) 英超联盟, a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA). We are helping develop tools to identify potential environmental risks of APIs and make these tools and data more accessible to all stakeholders.